{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:13:17Z","timestamp":1792696397355,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Osteogenesis imperfecta (OI) is a genetic disease characterized by bone fragility and recurrent fractures. Fracture rate has been advocated as an important endpoint for evaluating investigative therapies in OI, but real-world data on fracture burden in the OI population are lacking. This retrospective US claims database study aimed to quantify fracture rate and the occurrence of musculoskeletal disorders among patients with OI of all ages and in a subgroup of patients who were treated with \u22651 off-label therapies. 5722 patients with OI were identified in the IQVIA PharMetrics Plus database and 2095 (55.7% female; 35.1% peds; 20% with OI-related treatments; 87.1% commercial-insured) met eligibility criteria and were included in analyses. About 40% of patients with OI and 37% of those with off-label treatments had a fracture within 1\u00a0yr of diagnosis (index date for all OI) or treatment (index date for OI-treated). The annual average fracture rates of these groups were 0.84 and 0.98, respectively. Matched non-OI comparators had 3% fracture occurrence and a 0.03 annual fracture rate. Among patients with \u22651 fracture episode, the annualized median fracture rate was 2 per year for both OI and OI-treated cohorts and 1 for the non-OI cohort. Pediatric patients had the highest fracture occurrence and fracture rate, both among patients with OI and the subgroup of treated OI patients. Musculoskeletal disorders and diagnosed pain were more frequent in OI patients compared with the non-OI cohort, especially among pediatric age groups and adults 18-&amp;lt;45\u00a0yr. Pain and musculoskeletal disorders occurred frequently among OI patients, regardless of fracture occurrence, demonstrating impacts of OI beyond those that can be attributed to fractures. Together, these results highlight a high burden of fracture and other musculoskeletal disorders in a commercially insured population of OI patients, which are not effectively managed by current management strategies or off-label treatments.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf124","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T11:14:13Z","timestamp":1752837253000},"source":"Crossref","is-referenced-by-count":8,"title":["Real-world data of fracture rates and musculoskeletal disorders for patients living with osteogenesis imperfecta"],"prefix":"10.1093","volume":"9","author":[{"given":"Erru Christy","family":"Yang","sequence":"first","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc. , Global HEOR, Novato, CA 94949 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Ci\u011fero\u011flu","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc. , Global HEOR, Novato, CA 94949 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupal N","family":"Gupta","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc. , Global HEOR, Novato, CA 94949 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Shen","sequence":"additional","affiliation":[{"name":"Tianjin Happy Life Technology Co., Ltd. , Tianjin, 100083 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Sader","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc. , Global HEOR, Novato, CA 94949 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M","family":"Byers","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc. , Global HEOR, Novato, CA 94949 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0120-4535","authenticated-orcid":false,"given":"Mahim","family":"Jain","sequence":"additional","affiliation":[{"name":"Kennedy Krieger Institute, Johns Hopkins Medicine , Baltimore, MD 21205 ,","place":["United States"]},{"name":"Nemours Children\u2019s Hospital , Department of Orthopedic Surgery, Wilmington, DE 19803 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne M","family":"Franzone","sequence":"additional","affiliation":[{"name":"Kennedy Krieger Institute, Johns Hopkins Medicine , Baltimore, MD 21205 ,","place":["United States"]},{"name":"Nemours Children\u2019s Hospital , Department of Orthopedic Surgery, Wilmington, DE 19803 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"1","key":"2025091915532636900_ref1","doi-asserted-by":"publisher","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"2025091915532636900_ref2","volume-title":"Osteogenesis Imperfecta","author":"Subramanian","year":"2023"},{"issue":"5","key":"2025091915532636900_ref3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/medicina57050464","article-title":"Current overview of osteogenesis imperfecta","volume":"57","author":"Deguchi","year":"2021","journal-title":"Medicina."},{"issue":"4","key":"2025091915532636900_ref4","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1530\/EJE-20-0299","article-title":"Management of Endocrine Disease: osteogenesis imperfecta: an update on clinical features and therapies","volume":"183","author":"Marom","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025091915532636900_ref5","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1186\/s12889-024-20555-0","article-title":"The IMPACT survey: the humanistic impact of osteogenesis imperfecta in adults","volume":"24","author":"van","year":"2024","journal-title":"BMC Public Heal"},{"issue":"5","key":"2025091915532636900_ref6","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.049398","article-title":"Dissecting the phenotypic variability of osteogenesis imperfecta","volume":"15","author":"Garibaldi","year":"2022","journal-title":"Dis Model Mech"},{"issue":"1","key":"2025091915532636900_ref7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ajmg.a.63009","article-title":"A multicenter study to evaluate pain characteristics in osteogenesis imperfecta","volume":"191","author":"Celin","year":"2023","journal-title":"Am J M\u00e9d Genet Part A"},{"issue":"1","key":"2025091915532636900_ref8","doi-asserted-by":"publisher","first-page":"14025","DOI":"10.1038\/hgv.2014.25","article-title":"Osteogenesis imperfecta IIC caused by a novel heterozygous mutation in the C-propeptide region of COL1A1","volume":"1","author":"Takagi","year":"2014","journal-title":"Hum Genome Var"},{"issue":"1","key":"2025091915532636900_ref9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13023-024-03126-9","article-title":"The IMPACT survey: a mixed methods study to understand the experience of children, adolescents and adults with osteogenesis imperfecta and their caregivers","volume":"19","author":"Westerheim","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2025091915532636900_ref10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-023-02643-3","article-title":"Systematic review of health related-quality of life in adults with osteogenesis imperfecta","volume":"18","author":"Donald","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2025091915532636900_ref11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/jbmr.2920","article-title":"Fracture rates and fracture sites in patients with osteogenesis imperfecta: a Nationwide register-based cohort study","volume":"32","author":"Folkestad","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2025091915532636900_ref12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/ijms22020625","article-title":"Mechanisms of bone fragility: from osteogenesis imperfecta to secondary osteoporosis","volume":"22","author":"El-Gazzar","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2025091915532636900_ref13","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00223-024-01276-3","article-title":"Skeletal and non-skeletal phenotypes in children with osteogenesis imperfecta","volume":"115","author":"Marulanda","year":"2024","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2025091915532636900_ref14","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/ajmg.a.63132","article-title":"Nosology of genetic skeletal disorders: 2023 revision","volume":"191","author":"Unger","year":"2023","journal-title":"Am. J. M\u00e9d. Genet. Part A."},{"issue":"7","key":"2025091915532636900_ref15","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1210\/clinem\/dgad035","article-title":"Approach to the patient: pharmacological therapies for fracture risk reduction in adults with osteogenesis imperfecta","volume":"108","author":"Liu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025091915532636900_ref16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/MOP.0000000000000813","article-title":"Osteogenesis imperfecta: advancements in genetics and treatment","volume":"31","author":"Rossi","year":"2019","journal-title":"Curr Opin Pediatr"},{"issue":"6","key":"2025091915532636900_ref17","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00223-024-01188-2","article-title":"Current and developing pharmacologic agents for improving skeletal health in adults with osteogenesis imperfecta","volume":"115","author":"Liu","year":"2024","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2025091915532636900_ref18","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025091915532636900_ref19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3390\/jcm13041065","article-title":"New perspectives of therapies in osteogenesis imperfecta\u2014a literature review","volume":"13","author":"Dinulescu","year":"2024","journal-title":"J Clin Med"},{"issue":"5","key":"2025091915532636900_ref20","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00774-014-0618-2","article-title":"Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age","volume":"33","author":"Kusumi","year":"2015","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"2025091915532636900_ref21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta","volume":"86","author":"\u00c5str\u00f6m","year":"2002","journal-title":"Arch Dis Child"},{"issue":"10","key":"2025091915532636900_ref22","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"2016","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2025091915532636900_ref23","doi-asserted-by":"publisher","first-page":"e894","DOI":"10.1097\/MJT.0000000000000236","article-title":"Efficacy of bisphosphonates on bone mineral density and fracture rate in patients with osteogenesis imperfecta","volume":"23","author":"Shi","year":"2016","journal-title":"Am J Ther"},{"issue":"2","key":"2025091915532636900_ref24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/cge.12409","article-title":"A cross-sectional multicenter study of osteogenesis imperfecta in North America \u2013 results from the linked clinical research centers","volume":"87","author":"Patel","year":"2015","journal-title":"Clin Genet"},{"key":"2025091915532636900_ref25","article-title":"Healthcare resource use (HRU), treatment patterns and costs for patients living with osteogenesis imperfecta (OI) \u2013 results from a US retrospective claims database","author":"Yang","year":"2025","journal-title":"Under peer-review at Pharmacoeconomics Open"},{"key":"2025091915532636900_ref26","volume-title":"ASBMR Annual Symposium","author":"Liu","year":"2024 []"},{"issue":"Supplement_1","key":"2025091915532636900_ref27","doi-asserted-by":"crossref","first-page":"bvae163.358","DOI":"10.1210\/jendso\/bvae163.358","article-title":"6820 assessing the efficacy and safety of Setrusumab for osteogenesis imperfecta: updated phase 2 data from the phase 2\/3 orbit study","volume":"8","author":"Gottesman","year":"2024","journal-title":"J Endocr Soc"},{"issue":"9","key":"2025091915532636900_ref28","doi-asserted-by":"publisher","first-page":"e10782","DOI":"10.1002\/jbm4.10782","article-title":"The natural history of symptomatic fractures in children and adolescents with osteogenesis imperfecta type 1: a cohort study from Western Australia","volume":"7","author":"Joshi","year":"2023","journal-title":"JBMR Plus"},{"key":"2025091915532636900_ref29","article-title":"1.1 vertebral fracture. 2023 Jan 20"},{"issue":"40","key":"2025091915532636900_ref30","doi-asserted-by":"publisher","first-page":"e30256","DOI":"10.1097\/MD.0000000000030256","article-title":"Chronic pain in adults with osteogenesis imperfecta and its relationship to appraisal, coping, and quality of life: a cross-sectional study","volume":"101","author":"Cort\u00e9s","year":"2022","journal-title":"Medicine."}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf124\/63810337\/ziaf124.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/10\/ziaf124\/63810337\/ziaf124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/10\/ziaf124\/63810337\/ziaf124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T19:53:36Z","timestamp":1758311616000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf124\/8209743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf124","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,7,21]]},"article-number":"ziaf124"}}